|
1
|
Qian Y, Sang Y, Wang FX, Hong B, Wang Q,
Zhou X, Weng T, Wu Z, Zheng M, Zhang H, et al: Prognostic
significance of B7-H4 expression in matched primary pancreatic
cancer and liver metastases. Oncotarget. 7:72242–72249.
2016.PubMed/NCBI
|
|
2
|
Takamori H, Hiraoka T, Kanemitsu K, Tsuji
T, Hamada C and Baba H: Identification of prognostic factors
associated with early mortality after surgical resection for
pancreatic cancer - under-analysis of cumulative survival curve.
World J Surg. 30:213–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyanishi N, Nishi N, Abe H, Kashio Y,
Shinonaga R, Nakakita S, Sumiyoshi W, Yamauchi A, Nakamura T,
Hirashima M, et al: Carbohydrate-recognition domains of galectin-9
are involved in intermolecular interaction with galectin-9 itself
and other members of the galectin family. Glycobiology. 17:423–432.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsumoto R, Matsumoto H, Seki M, Hata M,
Asano Y, Kanegasaki S, Stevens RL and Hirashima M: Human ecalectin,
a variant of human galectin-9, is a novel eosinophil
chemoattractant produced by T lymphocytes. J Biol Chem.
273:16976–16984. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hirashima M, Kashio Y, Nishi N, Yamauchi
A, Imaizumi TA, Kageshita T, Saita N and Nakamura T: Galectin-9 in
physiological and pathological conditions. Glycoconj J. 19:593–600.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Seki M, Oomizu S, Sakata KM, Sakata A,
Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, et al:
Galectin-9 suppresses the generation of Th17, promotes the
induction of regulatory T cells, and regulates experimental
autoimmune arthritis. Clin Immunol. 127:78–88. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niki T, Tsutsui S, Hirose S, Aradono S,
Sugimoto Y, Takeshita K, Nishi N and Hirashima M: Galectin-9 is a
high affinity IgE-binding lectin with anti-allergic effect by
blocking IgE-antigen complex formation. J Biol Chem.
284:32344–32352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhu C, Anderson AC, Schubart A, Xiong H,
Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3
ligand galectin-9 negatively regulates T helper type 1 immunity.
Nat Immunol. 6:1245–1252. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Oomizu S, Arikawa T, Niki T, Kadowaki T,
Ueno M, Nishi N, Yamauchi A and Hirashima M: Galectin-9 suppresses
Th17 cell development in an IL-2-dependent but Tim-3-independent
manner. Clin Immunol. 143:51–58. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wiersma VR, de Bruyn M, Helfrich W and
Bremer E: Therapeutic potential of Galectin-9 in human disease. Med
Res Rev. 33(Suppl 1): E102–E126. 2013. View Article : Google Scholar
|
|
11
|
Fujihara S, Mori H, Kobara H, Rafiq K,
Niki T, Hirashima M and Masaki T: Galectin-9 in cancer therapy.
Recent Pat Endocr Metab Immune Drug Discov. 7:130–137. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kageshita T, Kashio Y, Yamauchi A, Seki M,
Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M:
Possible role of galectin-9 in cell aggregation and apoptosis of
human melanoma cell lines and its clinical significance. Int J
Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kuroda J, Yamamoto M, Nagoshi H, Kobayashi
T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima
M, et al: Targeting activating transcription factor 3 by Galectin-9
induces apoptosis and overcomes various types of treatment
resistance in chronic myelogenous leukemia. Mol Cancer Res.
8:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kobayashi T, Kuroda J, Ashihara E, Oomizu
S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N,
et al: Galectin-9 exhibits anti-myeloma activity through JNK and
p38 MAP kinase pathways. Leukemia. 24:843–850. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wiersma VR, de Bruyn M, Wei Y, van Ginkel
RJ, Hirashima M, Niki T, Nishi N, Zhou J, Pouwels SD, Samplonius
DF, et al: The epithelial polarity regulator LGALS9/galectin-9
induces fatal frustrated autophagy in KRAS mutant colon carcinoma
that depends on elevated basal autophagic flux. Autophagy.
11:1373–1388. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Irie A, Yamauchi A, Kontani K, Kihara M,
Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H, et al:
Galectin-9 as a prognostic factor with antimetastatic potential in
breast cancer. Clin Cancer Res. 11:2962–2968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang ZY, Dong JH, Chen YW, Wang XQ, Li
CH, Wang J, Wang GQ, Li HL and Wang XD: Galectin-9 acts as a
prognostic factor with antimetastatic potential in hepatocellular
carcinoma. Asian Pac J Cancer Prev. 13:2503–2509. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujita K, Iwama H, Sakamoto T, Okura R,
Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et
al: Galectin-9 suppresses the growth of hepatocellular carcinoma
via apoptosis in vitro and in vivo. Int J Oncol. 46:2419–2430.
2015.PubMed/NCBI
|
|
19
|
Kobayashi K, Morishita A, Iwama H, Fujita
K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H,
et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation
by inducing apoptosis but not cell cycle arrest. Oncol Rep.
34:1761–1770. 2015.PubMed/NCBI
|
|
20
|
Tadokoro T, Morishita A, Fujihara S, Iwama
H, Niki T, Fujita K, Akashi E, Mimura S, Oura K, Sakamoto T, et al:
Galectin-9: An anticancer molecule for gallbladder carcinoma. Int J
Oncol. 48:1165–1174. 2016.PubMed/NCBI
|
|
21
|
Takano J, Morishita A, Fujihara S, Iwama
H, Kokado F, Fujikawa K, Fujita K, Chiyo T, Tadokoro T, Sakamoto T,
et al: Galectin-9 suppresses the proliferation of gastric cancer
cells in vitro. Oncol Rep. 35:851–860. 2016.PubMed/NCBI
|
|
22
|
Zamore PD and Haley B: Ribo-gnome: The big
world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar
|
|
24
|
Nishi N, Itoh A, Fujiyama A, Yoshida N,
Araya S, Hirashima M, Shoji H and Nakamura T: Development of highly
stable galectins: Truncation of the linker peptide confers
protease-resistance on tandem-repeat type galectins. FEBS Lett.
579:2058–2064. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schutte B, Henfling M, Kölgen W, Bouman M,
Meex S, Leers MP, Nap M, Björklund V, Björklund P, Björklund B, et
al: Keratin 8/18 breakdown and reorganization during apoptosis. Exp
Cell Res. 297:11–26. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leers MP, Kölgen W, Björklund V, Bergman
T, Tribbick G, Persson B, Björklund P, Ramaekers FC, Björklund B,
Nap M, et al: Immunocytochemical detection and mapping of a
cytokeratin 18 neo-epitope exposed during early apoptosis. J
Pathol. 187:567–572. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cohen GM: Caspases: The executioners of
apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cai J, Yang J and Jones DP: Mitochondrial
control of apoptosis: The role of cytochrome c. Biochim Biophys
Acta. 1366:139–149. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Du C, Fang M, Li Y, Li L and Wang X: Smac,
a mitochondrial protein that promotes cytochrome c-dependent
caspase activation by eliminating IAP inhibition. Cell. 102:33–42.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Verhagen AM, Ekert PG, Pakusch M, Silke J,
Connolly LM, Reid GE, Moritz RL, Simpson RJ and Vaux DL:
Identification of DIABLO, a mammalian protein that promotes
apoptosis by binding to and antagonizing IAP proteins. Cell.
102:43–53. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suzuki Y, Imai Y, Nakayama H, Takahashi K,
Takio K and Takahashi R: A serine protease, HtrA2, is released from
the mitochondria and interacts with XIAP, inducing cell death. Mol
Cell. 8:613–621. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Chen J, Chang P, Leblanc A, Li D,
Abbruzzesse JL, Frazier ML, Killary AM and Sen S: MicroRNAs in
plasma of pancreatic ductal adenocarcinoma patients as novel
blood-based biomarkers of disease. Cancer Prev Res (Phila).
2:807–813. 2009. View Article : Google Scholar
|
|
33
|
Pineau P, Volinia S, McJunkin K, Marchio
A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM and
Dejean A: miR-221 overexpression contributes to liver
tumorigenesis. Proc Natl Acad Sci USA. 107:264–269. 2010.
View Article : Google Scholar :
|
|
34
|
Liang H, Wang F, Chu D, Zhang W, Liao Z,
Fu Z, Yan X, Zhu H, Guo W, Zhang Y, et al: miR-93 functions as an
oncomiR for the downregulation of PDCD4 in gastric carcinoma. Sci
Rep. 6:237722016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Milross CG, Mason KA, Hunter NR, Chung WK,
Peters LJ and Milas L: Relationship of mitotic arrest and apoptosis
to antitumor effect of paclitaxel. J Natl Cancer Inst.
88:1308–1314. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Toyota Y, Iwama H, Kato K, Tani J, Katsura
A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, et al:
Mechanism of gemcitabine-induced suppression of human
cholangiocellular carcinoma cell growth. Int J Oncol. 47:1293–1302.
2015.PubMed/NCBI
|
